Indications |
Oral Hypophosphataemia Adult: Up to 100 mmol of phosphate daily. Renal impairment: Dose reduction may be necessary. Intravenous Severe hypophosphataemia Adult: As monobasic potassium phosphate: Up to 9 mmol of phosphate given over 12 hr, repeat 12 hrly if needed. Alternatively, 0.2-0.5 mmol/kg phosphate (max: 50 mmol), may be given over 6-12 hr. Rectal Mild osmotic laxative for bowel evacuation and cleansing Adult: Usually contains monobasic and dibasic sodium phosphates but the composition and dosage may vary. Phosphate enemas work within 2-5 minutes. Use as directed. Renal impairment: Dose reduction may be necessary. Special Populations: Reduce doses in patients with renal function impairment. Incompatibility: Incompatible with calcium salts. |
Contraindications |
Severe renal function, congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon or hypomotility syndrome, hypertension, hyperkalaemia, oedema, low serum-calcium concentrations, infected phosphate renal calculi. |
Warnings / Precautions |
Chronic renal disease, pre-existing electrolyte disturbances. Concurrent admin with drugs that may affect electrolyte levels. Correct electrolyte abnormalities before initiating therapy. Monitor renal function, serum calcium, serum phosphorus, serum potassium, and serum sodium at periodic intervals during therapy. Caution in patients taking drugs that may prolong QT interval. Ensure adequate hydration. Pregnancy. Elderly or debilitated patients. |
Adverse Reactions |
Abdominal discomfort or pain, diarrhoea, nausea, vomiting, hypernatraemia, dehydration (with high doses). Convulsions, drowsiness, mood change, trembling, malaise, loss of appetite, muscle spasm (with long-term use). Less frequently, headaches, dizziness, mental confusion, seizures, weakness or heaviness of legs, muscle cramps, numbness, tingling, pain, arrhythmia; shortness of breath or troubled breathing; swelling of lower legs or feet; unusual weight gain, low urine output; unusual thirst; bone and joint pain. |
Overdose Reactions |
May lead to severe electrolyte disturbances, including hyperphosphataemia, hypocalcaemia, hypernatraemia, or hypokalaemia, as well as dehydration and hypovolaemia. May also lead to cardiac arrhythmias, seizure, renal failure and death. Monitor carefully and treat symptomatically until stable. |
Drug Interactions |
Concurrent use with aluminium, calcium, or magnesium salts will reduce absorption of phosphates. Vitamin D increases the GI absorption of phosphates and risk of hyperphosphataemia. Increased risk of hyperphosphataemia, hypocalcaemia, and hypernatraemia when used in patients receiving diuretics or drugs that may affect serum electrolytes. Increased risk of ectopic calcification when used concurrently with calcium supplements or calcium-containing antacids. See Below for More sodium phosphate Drug Interactions |
Food Interactions |
Decreased effects with milk or dairy products due to their calcium content. |
Mechanism of Actions |
Sodium phosphate can be used in the management of hypophosphataemia. It also acts as a mild osmotic laxative when given orally as dilute solutions or by the rectal route. Phosphate enemas or concentrated oral solutions are used for bowel cleansing before surgery or endoscopy procedures. Absorption: About 66% of an oral dose is absorbed from the GI tract. Metabolism: Excretion: Mainly excreted in the urine with the remaining dose via the faeces. |
Storage Conditions |
Oral: Store at 15-30°C. Rectal: Store at 15-30°C. |
ATC Classification |
A06AD17 - sodium phosphate ; Belongs to the class of osmotically acting laxatives. A06AG01 - sodium phosphate ; Belongs to the class of enemas. Used in the treatment of constipation. B05XA09 - sodium phosphate ; Belongs to the class of electrolyte solutions used in I.V. solutions. |
Storage |
Oral: Store at 15-30°C. Rectal: Store at 15-30°C. |
Available As |
|
Sodium Phosphate
Post Review about Sodium Phosphate Click here to cancel reply.
Sodium Phosphate Containing Brands
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.